Congress orders federal review of lung cancer research gaps in women

What it does

This bill directs the Secretary of Health and Human Services, working with Defense and Veterans Affairs, to review federal lung cancer research and prevention programs to identify gaps in knowledge about lung cancer in women and underserved populations, and to improve screening rates. The Secretary must report findings and recommendations to Congress within two years.

Why we flagged it

The bill is a straightforward mandate for federal health agencies to conduct a comprehensive review of lung cancer research and prevention efforts targeting women and underserved populations, with a reporting requirement to Congress. It is a transparency and accountability mechanism, not a funding authorization or regulatory change.

What the text implies

• The review may identify systemic gaps in how federal research funding has historically prioritized lung cancer in women, potentially exposing prior underinvestment or misallocation.
• Interagency coordination requirement (HHS, Defense, Veterans Affairs) may surface duplication or gaps in how different federal agencies approach lung cancer research, leading to consolidation or reallocation of resources.
• The two-year reporting deadline creates a fixed accountability checkpoint; failure to report or recommend changes will be publicly visible to Congress and the public.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

The bill creates a structured federal review to address a documented gap in lung cancer research and screening for women and underserved populations, potentially leading to improved prevention, earlier diagnosis, and better health outcomes. It imposes no restrictions on citizens' rights or access and generates no private financial giveaways.

Named in the bill

Department of Health and Human Services, Department of Defense, Department of Veterans Affairs, United States Preventive Services Task Force, Senate Committee on Health, Education, Labor, and Pensions, Senate Committee on Appropriations, House Committee on Energy and Commerce, House Committee on Appropriations

Where it stands

7 cosponsors: 5 Democrats, 2 Republicans.

• Mar 26, 2025 — Introduced · Congress.gov: “Introduced in Senate”
• Mar 26, 2025 — Referred to Senate Committee on Health, Education, Labor, and Pensions · Congress.gov: “Read twice and referred to the Committee on Health, Education, Labor, and Pensions”
• Jan 15, 2026 — Reported out of committee · Congress.gov: “Committee on Health, Education, Labor, and Pensions. Ordered to be reported with an amendment in the nature…”
• Jun 8, 2026 — Passed the Senate · Congress.gov: “Passed Senate with an amendment by Unanimous Consent. (consideration: CR S2669-2670; text: CR S2669-2670)”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

5 lobbying clients named this bill on 9 disclosure filings across 2 quarters, Dec 2025 to Jun 2026. Those filings disclosed $5,372,753 in lobbying spend. A filing names 60 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 78% of bills with at least one filing.

Tina Smith, the sponsor, reported $-40,500 in PAC receipts in the 2026 cycle.

• American Cancer Society Cancer Action Network Inc — $3,620,000 on 2 filings
• American Association of Nurse Practitioners — $950,000 on 2 filings
• Earthjustice Action — $376,600 on 2 filings
• The Society of Thoracic Surgeons — $366,153 on 2 filings
• Hadassah, the Women's Zionist Organization of America, Inc. — $60,000 on 1 filing

Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.